Targeting BCMA with bispecific antibodies in R/R myeloma
Saad Usmani, MD, of the University of North Carolina School of Medicine, Chapel Hill, NC, presents exciting results from clinical trials for bispecific antibodies targeting BCMA at the European School...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Monoclonal antibodies: current and future potential
Approved monoclonal antibodies for multiple myeloma (MM) are currently available, yet there are still gaps to explore in this therapeutic area for MM. At the European School of Haematology (ESH) Inter...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Plasma cell leukemia and extramedullary disease in multiple myeloma
What is the current treatment landscape for plasma cell leukemia and extramedullary disease in multiple myeloma (MM)? We spoke to Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Maria-Victoria Mateos, MD, PhD, of the University of Salamanca, Salamanca, Spain, discusses the updated analysis of the CASTOR trial (NCT02136134) with us at the European School of Haematology (ESH) I...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Future treatment combinations for myeloma
Multiple myeloma (MM) therapy has evolved rapidly in recent years, and is showing no sign of slowing. Here, Kenneth Anderson, MD, from Harvard Medical School, Boston, MA, discusses interesting future ...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Continuous vs. fixed duration therapy for multiple myeloma?
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jess San Miguel, MD, PhD, of the University of Navarra, Pamplona, ...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Treatment sequencing in multiple myeloma: a multitude of options
Heinz Ludwig, MD, PhD, from Wilhelminen Cancer Research Institute, Vienna, Austria, discusses treatment sequencing in multiple myeloma (MM). Dr Ludwig covers the many options available to treat MM, pa...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
The evolving imaging of multiple myeloma
Speaking from the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Evangelos Terpos, MD, PhD, of the University of Athens, Athens, Gre...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
What is the role of PET/CT in myeloma management?
Functional imaging techniques serve an essential role in diagnostics. Here, Elena Zamagni, MD, PhD, of the University of Bologna, Bologna, Italy, highlights the important applications of PET/CT in mul...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Treatment options for high-risk myeloma
Annemiek Broyl, MD, PhD, from Erasmus Medical Center and University, Rotterdam, Netherlands, discusses how to treat high-risk multiple myeloma (MM). Dr Broyl highlights trials such as MUK Nine (NCT031...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Geriatric assessment in multiple myeloma: is it required?
Alessandra Larocca, MD, PhD, of the University Hospital Citt della Salute e della Scienza, Torino, Italy, discusses the importance of geriatric assessment in multiple myeloma (MM). In addition, Dr La...
Author: VJHemOnc
Added: 10/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - October 10, 2018 Category: Cancer & Oncology Source Type: podcasts
IMiDs induce hematopoietic malignancies
The mechanism for the previously unknown occurrence of thrombocytopenia and neutropenia in patients with myeloma treated with immunomodulatory drugs (IMiDs) has finally been understood from clinical t...
Author: VJHemOnc
Added: 09/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 28, 2018 Category: Cancer & Oncology Source Type: podcasts
Imaging modalities and treatment breakthroughs in myeloma bone disease
In this interview, recorded at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Meletios Dimopoulos, MD, of the University of Athens School of Medicine, Athens, Greece, g...
Author: VJHemOnc
Added: 09/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 19, 2018 Category: Cancer & Oncology Source Type: podcasts
Anti-BCMA CAR T-cells in myeloma: what data do we have so far?
BCMA is an exciting therapeutic target for multiple myeloma (MM). Here, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses current trials of CAR T-cell products that are targeting BCMA, and...
Author: VJHemOnc
Added: 09/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 14, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy of myeloma: BCMA/SLAMF7 CAR T-cells & BiTEs
Multiple myeloma (MM) is at the forefront of immunotherapeutic developments, including T-cell therapies and bispecific antibodies. Here, our expert panel discuss BCMA and SLAMF7 targeting CAR T-cells,...
Author: VJHemOnc
Added: 09/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - September 14, 2018 Category: Cancer & Oncology Source Type: podcasts
